Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 26, 2015 - Issue 6
Submit an article Journal homepage
517
Views
26
CrossRef citations to date
0
Altmetric
Psoriasis

Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice

Jose-Manuel CarrascosaDepartment of Dermatology, Hospital Universitari Germans Trías i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain, Correspondence[email protected]
,
Ignacio Garcia-DovalDepartment of Dermatology, Research Unit, Fundación Academia Española de Dermatología y Venereología [Spanish Academy of Dermatology and Venereology Foundation], Madrid, Spain,
,
Beatriz Pérez-ZafrillaDepartment of Dermatology, Research Unit, Fundación Academia Española de Dermatología y Venereología [Spanish Academy of Dermatology and Venereology Foundation], Madrid, Spain, ;Research Unit, Complejo Hospitalario Universitario de Albacete, Albacete, Spain,
,
Gregorio CarreteroDepartment of Dermatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain,
,
Francisco VanaclochaDepartment of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain,
,
Esteban DaudénDepartment of Dermatology, Hospital Universitario la Princesa, Madrid, Spain,
,
Pablo De la Cueva-DobaoDepartamento de Dermatología, Hospital Infanta Leonor, Madrid, Spain,
,
Isabel BelinchónHospital General Universitario de Alicante, Alicante, Spain,
,
Merce AlsinaDepartment of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain,
,
Jose-Luis López-EstebaranzHospital Universitario Fundación de Alcorcón, Madrid, Spain, and
,
Marta FerránDepartment of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
,
Rosa TorradoDepartment of Dermatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain,
,
Raquel RiveraDepartment of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain,
,
Cristina CarazoDepartment of Dermatology, Hospital Universitario la Princesa, Madrid, Spain,
,
Lorena BarbozaDepartment of Dermatology, Hospital Universitari Germans Trías i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain,
,
Carlos FerrándizDepartment of Dermatology, Hospital Universitari Germans Trías i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain,
& the BIOBADADERM Study Group show all
Pages 502-506 | Received 31 Dec 2014, Accepted 20 Mar 2015, Published online: 17 Apr 2015

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Valentina Perrone, Serena Losi, Silvia Sabatino, Maurizio Mezzetti, Melania Dovizio, Diego Sangiorgi & Luca Degli Esposti. (2023) Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population. Psoriasis: Targets and Therapy 13, pages 1-9.
Read now
Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg & Jeff Crowley. (2023) Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment 34:1.
Read now
Ambra Di Altobrando, Michela Magnano, Annamaria Offidani, Aurora Parodi, Annalisa Patrizi, Anna Campanati, Martina Burlando & Federico Bardazzi. (2022) Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a ‘perceived satisfaction’: a multicentric study. Journal of Dermatological Treatment 33:1, pages 415-419.
Read now
Mina Amin, Erica B. Lee, Tina Bhutani & Jashin J. Wu. (2019) Review of European registries for psoriasis. Journal of Dermatological Treatment 30:3, pages 227-236.
Read now
Rosa M. Romero-Jimenez, Vicente Escudero-Vilaplana, Ofelia Baniandres Rodriguez, Estela García Martín, Ana Mateos Mayo & Maria Sanjurjo Saez. (2018) Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis. Journal of Dermatological Treatment 29:8, pages 792-796.
Read now
G. Carretero, L. Puig, J. M. Carrascosa, L. Ferrándiz, R. Ruiz-Villaverde, P. de la Cueva, I. Belinchon, E. Vilarrasa, R. del Rio, J. L. Sánchez-Carazo, A. López-Ferrer, F. Peral, S. Armesto, N. Eiris, J. Mitxelena, J. Vilar-Alejo, M. A. Martin & C. Soria. (2018) Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. Journal of Dermatological Treatment 29:4, pages 334-346.
Read now
J. M. Carrascosa, M. Toro Montecinos, F. Ballescá, A. Teniente Serra, E. Martínez Cáceres & C. Ferrándiz. (2018) Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. Journal of Dermatological Treatment 29:2, pages 140-144.
Read now
Lluís Puig, Jaume Notario, Alberto Jiménez-Morales, David Moreno-Ramírez, Anna López-Ferrer, Irmina Gozalbo, Míriam Prades, Luis Lizán & Carles Blanch. (2017) Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. Journal of Dermatological Treatment 28:7, pages 623-630.
Read now

Articles from other publishers (18)

E. Daudén, D. Vidal, A. Romero, M.T. Bordel, R. Rivera, J. Márquez, E. Zamora, L. Martinez, M.J. Ocaña, C. Vila, P. Iribarren, N. Corona & A. Zulaica. (2023) [Artículo traducido] Gravedad de la psoriasis, calidad de vida relacionada con la salud, productividad laboral y deterioro de la actividad en pacientes con psoriasis moderada a grave que reciben tratamiento sistémico: datos de la vida real de la práctica clínica en España. Actas Dermo-Sifiliográficas.
Crossref
Ángela María Londoño-García, María Fernanda Suárez-Giraldo, Lina María Colmenares-Roldán, Juliana Madrigal-Cadavid, Jorge Estrada, Paulo Giraldo & Daniel Jaramillo-Arroyave. (2022) Is it possible to optimize biologic therapy in patients with psoriasis?. Revista Colombiana de Reumatología.
Crossref
Alexander Egeberg, Jonatan Freilich, M. Natalia Stelmaszuk, Rikke Kongerslev, Eydna Apol, Jes Birger Hansen & Lars-Åke Levin. (2022) Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study. Clinical and Experimental Dermatology 47:11, pages 1968-1975.
Crossref
Alessio Gambardella, Gaetano Licata & Anne Sohrt. (2021) Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review. Dermatology and Therapy 11:4, pages 1141-1156.
Crossref
C. A. J. Michielsens, M. E. van Muijen, L. M. Verhoef, J. M. P. A. van den Reek & E. M. G. J de Jong. (2021) Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. Drugs 81:3, pages 349-366.
Crossref
Ester Muñoz-Aceituno, Luisa Martos-Cabrera, María Carmen Ovejero-Benito, Alejandra Reolid, Francisco Abad-Santos & Esteban Daudén. (2020) Pharmacogenetics Update on Biologic Therapy in Psoriasis. Medicina 56:12, pages 719.
Crossref
B. Strober, A. Menter, C. Leonardi, K. Gordon, J. Lambert, L. Puig, H. Photowala, M. Longcore, T. Zhan & P. Foley. (2020) Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. Journal of the European Academy of Dermatology and Venereology 34:12, pages 2830-2838.
Crossref
Mar Llamas‐Velasco & Esteban Daudén. (2020) Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival. Dermatologic Therapy 33:6.
Crossref
Liqing Shi, Ni Lian, Lihao Liu & Min Chen. (2020) Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity. Dermatologic Therapy 33:4.
Crossref
M.C. Ovejero‐Benito, E. Muñoz‐Aceituno, D. Sabador, A. Reolid, M. Llamas‐Velasco, R. Prieto‐Pérez, F. Abad‐Santos & E. Daudén. (2020) Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate‐to‐severe psoriasis. Journal of the European Academy of Dermatology and Venereology 34:6.
Crossref
Erica B. Lee, Logan W. Thomas, Alexander Egeberg & Jashin J. Wu. (2020) Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review. Journal of Psoriasis and Psoriatic Arthritis 5:2, pages 52-53.
Crossref
Peter A. Lio. (2020) Considerations in Weaning or Withdrawing Dupilumab Therapy—Nothing Is Forever. JAMA Dermatology 156:2, pages 119.
Crossref
Celia Gómez‐de Castro, Marc Mir‐Bonafé, Aránzazu Arias‐Martínez, Pablo Martínez‐Camblor, Susana Díaz‐Coto & Jorge Santos‐Juanes. (2019) Comment on ‘Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments'. Australasian Journal of Dermatology 60:3.
Crossref
E.B. Lee, L.W. Thomas, A. Egeberg & J.J. Wu. (2018) Dosage adjustments in patients with psoriasis on adalimumab - a retrospective chart review. Journal of the European Academy of Dermatology and Venereology 32:7, pages e292-e293.
Crossref
Ji S. van Bezooijen, Martijn B. A. van Doorn, Marco W. J. SchreursBirgit C. P. KochHenk te Velthuis, Errol P. PrensTeun van Gelder. (2017) Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study. Therapeutic Drug Monitoring 39:4, pages 379-386.
Crossref
J.M. Carrascosa, M. Galán, R. de Lucas, A. Pérez-Ferriols, M. Ribera & I. Yanguas. (2016) Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II). Actas Dermo-Sifiliográficas (English Edition) 107:9, pages 712-729.
Crossref
J.M. Carrascosa, M. Galán, R. de Lucas, A. Pérez-Ferriols, M. Ribera & I. Yanguas. (2016) Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales (II). Actas Dermo-Sifiliográficas 107:9, pages 712-729.
Crossref
L. Eissing, S.J. Rustenbach, M. Krensel, N. Zander, C. Spehr, M.A. Radtke, L. Naldi & M. Augustin. (2016) Psoriasis registries worldwide: systematic overview on registry publications. Journal of the European Academy of Dermatology and Venereology 30:7, pages 1100-1106.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.